What changed: Myeloproliferative neoplasms (PV, ET, myelofibrosis)

When this page itself was last checked or edited.

Erythrocytosis in adults with polycythaemia vera

VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.

Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.

Myelofibrosis with moderate-to-severe anaemia

Intermediate/high-risk myelofibrosis with anaemia

MOMENTUM: symptom, spleen and transfusion-independence benefit versus danazol.

Intermediate/high-risk myelofibrosis with platelets <50×10⁹/L

A milestone in how this cancer is treated.

Myelofibrosis, JAK-inhibitor-naive or after ruxolitinib

Polycythaemia vera

PROUD/CONTINUATION-PV: superior long-term haematologic and molecular response versus hydroxyurea.

By 36 months, complete haematological response with improved disease burden and molecular response were both more frequent with ropeginterferon than hydroxyurea.

Intermediate-2/high-risk primary or secondary myelofibrosis

Polycythaemia vera without symptomatic splenomegaly

JAKARTA; the second JAK inhibitor after an eight-year gap.

Composite response at week 32: 21% vs 1%; haematocrit control 60% vs 20%.

Polycythaemia vera after hydroxyurea

Cardiovascular death or major thrombosis 2.

Klampfl and Nangalia find CALR exon 9 mutations in most JAK2-negative ET/PMF.

CYTO-PV: keeping haematocrit <45% cuts cardiovascular death and major thrombosis in PV.

COMFORT-I/II: spleen and symptom benefit in myelofibrosis; the first JAK inhibitor.

Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.

Four groups report the mutation in most PV and half of ET/PMF; the first molecular marker for BCR-ABL1-negative MPN.

Elevated platelet counts in at-risk essential thrombocythaemia intolerant of or inadequately controlled by current therapy (Xagrid)

Thrombocythaemia secondary to myeloproliferative neoplasms

Polycythaemia vera; chronic myeloid leukaemia refractory to busulfan (historic label)

Proposes that PV, ET, CML and myelofibrosis are related myeloproliferative disorders.